Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptide Fragments | 44 | 2017 | 519 | 5.340 |
Why?
|
| Angiotensin I | 40 | 2017 | 342 | 4.900 |
Why?
|
| Angiotensin II | 35 | 2015 | 382 | 3.390 |
Why?
|
| Muscle, Smooth, Vascular | 11 | 2008 | 80 | 1.560 |
Why?
|
| Receptors, Angiotensin | 15 | 2003 | 90 | 1.300 |
Why?
|
| Peptidyl-Dipeptidase A | 10 | 2017 | 203 | 1.100 |
Why?
|
| Antihypertensive Agents | 7 | 2015 | 379 | 1.100 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 600 | 0.960 |
Why?
|
| Cell Proliferation | 4 | 2014 | 603 | 0.920 |
Why?
|
| Animals | 46 | 2016 | 7552 | 0.890 |
Why?
|
| Rats | 26 | 2015 | 1750 | 0.870 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 91 | 0.850 |
Why?
|
| Fibroblasts | 2 | 2012 | 117 | 0.810 |
Why?
|
| Astrocytes | 5 | 2005 | 53 | 0.770 |
Why?
|
| MAP Kinase Signaling System | 5 | 2015 | 63 | 0.760 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 388 | 0.760 |
Why?
|
| Cells, Cultured | 16 | 2012 | 793 | 0.750 |
Why?
|
| Cell Division | 6 | 2005 | 104 | 0.680 |
Why?
|
| Hypertension | 8 | 2015 | 994 | 0.670 |
Why?
|
| Dual Specificity Phosphatase 1 | 5 | 2015 | 29 | 0.650 |
Why?
|
| Myocytes, Cardiac | 2 | 2008 | 107 | 0.630 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2012 | 813 | 0.600 |
Why?
|
| Renin-Angiotensin System | 7 | 2012 | 267 | 0.590 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2009 | 121 | 0.580 |
Why?
|
| Blood Pressure | 7 | 2015 | 910 | 0.560 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2012 | 123 | 0.560 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 303 | 0.560 |
Why?
|
| Peptide Hormones | 1 | 2014 | 10 | 0.550 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 493 | 0.530 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 103 | 0.530 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 6 | 0.500 |
Why?
|
| Angiotensins | 3 | 2011 | 68 | 0.500 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2015 | 45 | 0.490 |
Why?
|
| Carboxypeptidases | 3 | 2005 | 32 | 0.450 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2008 | 38 | 0.440 |
Why?
|
| Imidazoles | 11 | 2008 | 118 | 0.440 |
Why?
|
| Autonomic Nervous System | 1 | 2011 | 43 | 0.440 |
Why?
|
| RNA, Messenger | 12 | 2009 | 544 | 0.440 |
Why?
|
| Losartan | 13 | 2008 | 89 | 0.430 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 458 | 0.420 |
Why?
|
| Ventricular Remodeling | 4 | 2011 | 92 | 0.410 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2008 | 5 | 0.380 |
Why?
|
| Fibrosis | 5 | 2016 | 117 | 0.380 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 492 | 0.380 |
Why?
|
| Brain | 3 | 2011 | 964 | 0.380 |
Why?
|
| Medulla Oblongata | 5 | 2012 | 55 | 0.370 |
Why?
|
| Signal Transduction | 7 | 2012 | 743 | 0.360 |
Why?
|
| Animals, Newborn | 5 | 2012 | 115 | 0.360 |
Why?
|
| Tetrazoles | 10 | 2006 | 101 | 0.360 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 81 | 0.360 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2009 | 137 | 0.350 |
Why?
|
| Heart Ventricles | 1 | 2008 | 144 | 0.350 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 6 | 2008 | 108 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2012 | 39 | 0.340 |
Why?
|
| Phospholipase D | 2 | 1995 | 5 | 0.310 |
Why?
|
| Phosphorylation | 4 | 2015 | 256 | 0.310 |
Why?
|
| Cell Line, Tumor | 5 | 2012 | 715 | 0.290 |
Why?
|
| Mice, Nude | 5 | 2012 | 293 | 0.280 |
Why?
|
| Vasoconstrictor Agents | 3 | 2015 | 57 | 0.270 |
Why?
|
| Renin | 6 | 2012 | 164 | 0.260 |
Why?
|
| Cardiomegaly | 1 | 2011 | 41 | 0.230 |
Why?
|
| Mice | 7 | 2016 | 2366 | 0.230 |
Why?
|
| Humans | 20 | 2017 | 29288 | 0.220 |
Why?
|
| Endothelin-1 | 2 | 2012 | 24 | 0.220 |
Why?
|
| Myocardium | 3 | 2012 | 241 | 0.210 |
Why?
|
| Male | 18 | 2016 | 18658 | 0.210 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 56 | 0.200 |
Why?
|
| Rats, Inbred Lew | 4 | 2015 | 146 | 0.200 |
Why?
|
| Carotid Artery Injuries | 1 | 1999 | 11 | 0.200 |
Why?
|
| Flavonoids | 2 | 2008 | 20 | 0.190 |
Why?
|
| Tunica Intima | 1 | 1999 | 84 | 0.190 |
Why?
|
| Carotid Artery, Common | 1 | 1999 | 47 | 0.190 |
Why?
|
| Baroreflex | 2 | 2011 | 90 | 0.190 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2012 | 32 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 88 | 0.180 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2017 | 6 | 0.180 |
Why?
|
| Endothelium, Vascular | 3 | 1999 | 148 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2012 | 259 | 0.180 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 40 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2008 | 162 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 83 | 0.170 |
Why?
|
| Binding, Competitive | 4 | 2001 | 36 | 0.170 |
Why?
|
| Hypertension, Renal | 2 | 2006 | 38 | 0.160 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 4 | 0.160 |
Why?
|
| Spasm | 1 | 2016 | 5 | 0.160 |
Why?
|
| Prostaglandins | 4 | 2003 | 16 | 0.160 |
Why?
|
| Pyridines | 4 | 2005 | 89 | 0.150 |
Why?
|
| Smad2 Protein | 1 | 2015 | 7 | 0.150 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 5 | 0.150 |
Why?
|
| Arterioles | 1 | 2015 | 14 | 0.150 |
Why?
|
| Smad3 Protein | 1 | 2015 | 11 | 0.150 |
Why?
|
| Neoplasms | 2 | 2014 | 676 | 0.140 |
Why?
|
| Pancreas | 1 | 1995 | 79 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 7 | 2010 | 167 | 0.140 |
Why?
|
| Receptor, Angiotensin, Type 1 | 6 | 2004 | 110 | 0.140 |
Why?
|
| Epoprostenol | 4 | 1997 | 10 | 0.140 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 267 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2015 | 387 | 0.130 |
Why?
|
| Kinetics | 3 | 2006 | 190 | 0.120 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 9 | 0.120 |
Why?
|
| Osteoclasts | 1 | 2012 | 22 | 0.120 |
Why?
|
| Calcium | 6 | 1995 | 322 | 0.120 |
Why?
|
| Cerebellum | 2 | 2005 | 30 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2010 | 281 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 327 | 0.110 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 8 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2012 | 112 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 29 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2001 | 145 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2012 | 25 | 0.110 |
Why?
|
| DNA | 1 | 2012 | 207 | 0.110 |
Why?
|
| Collagen | 1 | 2012 | 232 | 0.110 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2009 | 35 | 0.100 |
Why?
|
| Chorioallantoic Membrane | 1 | 2009 | 4 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 38 | 0.100 |
Why?
|
| Type C Phospholipases | 2 | 2001 | 9 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 37 | 0.100 |
Why?
|
| Chick Embryo | 1 | 2009 | 73 | 0.100 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 115 | 0.100 |
Why?
|
| Valine | 2 | 2006 | 29 | 0.100 |
Why?
|
| Butadienes | 1 | 2008 | 7 | 0.100 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 17 | 0.100 |
Why?
|
| Vanadates | 1 | 2008 | 3 | 0.100 |
Why?
|
| Okadaic Acid | 1 | 2008 | 4 | 0.100 |
Why?
|
| Nitriles | 1 | 2008 | 23 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 254 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 105 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2016 | 491 | 0.090 |
Why?
|
| Leucine | 1 | 2008 | 31 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 101 | 0.090 |
Why?
|
| Solitary Nucleus | 1 | 2008 | 40 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2009 | 173 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 192 | 0.090 |
Why?
|
| Biphenyl Compounds | 3 | 1997 | 24 | 0.090 |
Why?
|
| Heart Rate | 2 | 2008 | 358 | 0.090 |
Why?
|
| Neurons | 1 | 1991 | 390 | 0.090 |
Why?
|
| Cattle | 2 | 1997 | 91 | 0.080 |
Why?
|
| Oligopeptides | 4 | 1994 | 55 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 1040 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2006 | 105 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 1995 | 133 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 36 | 0.070 |
Why?
|
| Aorta, Thoracic | 2 | 1996 | 79 | 0.070 |
Why?
|
| Rats, Inbred SHR | 3 | 2009 | 71 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 674 | 0.070 |
Why?
|
| Culture Media | 1 | 2004 | 38 | 0.070 |
Why?
|
| DNA Replication | 1 | 2004 | 23 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2004 | 72 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 5 | 0.070 |
Why?
|
| Dinoprostone | 3 | 1993 | 32 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2003 | 45 | 0.070 |
Why?
|
| Cytosol | 2 | 1995 | 27 | 0.070 |
Why?
|
| Aging | 1 | 2011 | 930 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 730 | 0.070 |
Why?
|
| Animals, Genetically Modified | 4 | 2006 | 94 | 0.060 |
Why?
|
| Pregnancy | 1 | 2005 | 761 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2011 | 85 | 0.060 |
Why?
|
| Angiotensinogen | 2 | 2012 | 119 | 0.060 |
Why?
|
| Vasodilator Agents | 2 | 1998 | 60 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2011 | 206 | 0.060 |
Why?
|
| Bradykinin | 2 | 1998 | 25 | 0.050 |
Why?
|
| Kidney | 2 | 2003 | 481 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2001 | 307 | 0.050 |
Why?
|
| Models, Biological | 2 | 2009 | 373 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 485 | 0.050 |
Why?
|
| Peptides | 2 | 2009 | 110 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 89 | 0.050 |
Why?
|
| Catheterization | 1 | 1999 | 62 | 0.050 |
Why?
|
| Rats, Inbred WKY | 2 | 1995 | 36 | 0.050 |
Why?
|
| Monocytes | 1 | 1999 | 114 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1998 | 36 | 0.040 |
Why?
|
| Protein Stability | 1 | 2017 | 27 | 0.040 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1997 | 1 | 0.040 |
Why?
|
| Neprilysin | 2 | 2008 | 38 | 0.040 |
Why?
|
| Hypothalamus | 1 | 1997 | 21 | 0.040 |
Why?
|
| Female | 5 | 2010 | 18970 | 0.040 |
Why?
|
| Thymidine | 1 | 1996 | 7 | 0.040 |
Why?
|
| Cell Count | 1 | 1996 | 53 | 0.040 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 41 | 0.040 |
Why?
|
| Lisinopril | 2 | 2006 | 35 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 110 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 1997 | 139 | 0.040 |
Why?
|
| Hindlimb | 1 | 2016 | 57 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 85 | 0.040 |
Why?
|
| Reference Values | 1 | 2016 | 245 | 0.040 |
Why?
|
| Random Allocation | 1 | 2016 | 229 | 0.040 |
Why?
|
| Diglycerides | 1 | 1994 | 4 | 0.040 |
Why?
|
| 1-Sarcosine-8-Isoleucine Angiotensin II | 2 | 1991 | 4 | 0.040 |
Why?
|
| Hybrid Cells | 2 | 1991 | 8 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 537 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 502 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 14 | 0.030 |
Why?
|
| Ion Channels | 1 | 2012 | 25 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2012 | 80 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 72 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2004 | 26 | 0.030 |
Why?
|
| Biotransformation | 1 | 1991 | 6 | 0.030 |
Why?
|
| Angiotensin III | 1 | 1991 | 2 | 0.030 |
Why?
|
| Prostaglandins F | 1 | 1991 | 3 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 70 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1991 | 6 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 162 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1991 | 31 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 1999 | 1102 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 81 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 211 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 46 | 0.030 |
Why?
|
| Fibronectins | 1 | 2010 | 33 | 0.030 |
Why?
|
| Mitochondria | 1 | 2012 | 181 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 85 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 1990 | 20 | 0.030 |
Why?
|
| Cell Line | 1 | 1991 | 432 | 0.030 |
Why?
|
| Glioma | 1 | 1991 | 137 | 0.030 |
Why?
|
| Membranes | 1 | 2008 | 12 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 13 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 10068 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2006 | 9 | 0.020 |
Why?
|
| Animals, Congenic | 1 | 2006 | 20 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 28 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 44 | 0.020 |
Why?
|
| Podocytes | 1 | 2006 | 26 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 36 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 11572 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2004 | 6 | 0.020 |
Why?
|
| Albuminuria | 1 | 2006 | 209 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 1764 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 34 | 0.020 |
Why?
|
| Ligation | 1 | 2004 | 60 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2004 | 395 | 0.020 |
Why?
|
| Protein Binding | 1 | 2003 | 196 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2004 | 191 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 2001 | 2 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 28 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2001 | 23 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 62 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 3924 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 2105 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1999 | 2 | 0.010 |
Why?
|
| Hydralazine | 1 | 1999 | 9 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 23 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 26 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 105 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 169 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 8719 | 0.010 |
Why?
|
| Immune Sera | 1 | 1995 | 10 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 193 | 0.010 |
Why?
|
| Aorta | 1 | 1993 | 116 | 0.010 |
Why?
|
| 4-Chloromercuribenzenesulfonate | 1 | 1990 | 1 | 0.010 |
Why?
|
| Enalaprilat | 1 | 1990 | 1 | 0.010 |
Why?
|
| Dipeptides | 1 | 1990 | 10 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1990 | 26 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 84 | 0.010 |
Why?
|